The associations of pergolide and valvular heart disease have been reported from 2007 according to Taiwan National Adverse Drug Reactions Reporting System. However, data regarding relative risks of pergolide induced valvular heart disease are limited. evidence, the outcomes of observational studies indicated no significant in increasing risk of valvular heart disease with pergolide. Nevertheless, evidence does not still unclearly understand the correlation and mechanism of pergolide with valvular heart disease. It is suggested that echocardiogram and a routine cardiovascular evaluation must be examined before pergolide prescribed.Patients also have to be monitored for signs and symptoms of valvulopathy, including dyspnea, palpitation and fatigue. If patients develop these signs or symptoms, consideration must be given to suspending treatment with pergolide until a full diagnostic evaluation, including echocardiogram, has been performed. In addition,long-term safety assessment and different fields of research have to be conducted and analyzed to assess the correlation of pergolide use and valvular heart disease.